TAICHUNG, December 9, 2025 /PRNewswire/ — Supported by certification from a new medical association, Insumate® becomes the only bitter melon peptide recognized globally by the FDA-NDI, SNQ and the Taiwan Complementary Medicine Society (TCMS).
As the global demand for scientifically validated metabolic health ingredients continues to increase, Greenyn Biotechnology Co., Ltd., a publicly traded biotechnology company in Taiwan, today announced that its lead ingredient Insumate® mcIRBP-19 Bitter Melon Peptide has been awarded “Certification of Excellent Product Quality” by the Taiwan Complementary Medicine Society (TCMS).
This recognition positions Insumate® as the only bitter melon peptide ingredient to have simultaneously obtained:
- Certification from the Taiwan Complementary Medicine Society (TCMS)
- Approval of new food ingredients (NDI) by the US FDA
- National Quality Symbol (SNQ)
This combination of recognitions is currently unmatched among functional ingredients derived from bitter melon worldwide.
According to Greenyn Biotechnology’s Managing Director and Head of R&D, Dr. Pang-Kuei Hsu, this certification confirms that the ingredient has passed rigorous reviews covering raw materials, manufacturing, scientific validation and clinical research, making it a trusted benchmark for healthcare professionals selecting nutritional support ingredients. Greenyn hopes the new certification will further strengthen the medical community’s confidence in clinically supported functional ingredients and accelerate the company’s expansion in the Asia-Pacific region.
Growing Demand for Metabolic Health Solutions: Greenyn Sets a New Benchmark with Evidence-Based Research on Bitter Melon Peptides
Recent data from the International Diabetes Federation (IDF) highlights the growing global need for metabolic health solutions. In 2024, 589 million adults worldwide, or about 1 in 9 people, were living with diabetes, and this figure is expected to rise to 853 million by 2050.
More than 12 years of research, three major certifications: Insumate® mcIRBP-19 strengthens the confidence of professionals and consumers
Greenyn spent over a decade collaborating with medical schools and biomedical research institutes in Taiwan to develop Insumate®. Using low-temperature supercritical extraction, the team successfully isolated the bioactive peptide mcIRBP-19, a precisely sequenced small-molecule peptide extracted from bitter melon. This solvent-free process preserves the integrity and bioactivity of the peptides, distinguishing it from conventional solvent extraction methods that produce undefined polypeptide mixtures.
Patented 19-peptide interacts directly with insulin receptors to support glucose control
Greenyn’s research shows that mcIRBP-19 interacts directly with insulin receptors through a unique binding site, activating downstream signaling pathways that support efficient glucose utilization.
Clinical studies conducted in Taiwan demonstrated that consumption of mcIRBP-19 for 12 weeks resulted in:
- approximately 14% reduction in fasting blood sugar
- more than 22% reduction in triglycerides
- significant improvement in HbA1c
For populations in poor health, including aging individuals or those experiencing metabolic slowdown, international studies have shown that high doses of bitter melon components help maintain stable blood sugar levels and significantly improve HbA1c and triglycerides in older subgroups.
To date, more than seven index articles on IBS and three large-scale clinical trials involving more than 200 subjects have validated its effectiveness.
Dr. Tao-Ming Chen, President of the Taiwan Complementary Medicine Society (TCMS), emphasized:
“Products certified by the Taiwan Complementary Medicine Society meet strict standards of scientific validation, clinical evidence and quality management, providing healthcare professionals with a trusted benchmark for supportive nutrition. In recent years, bitter melon has become one of the most studied ingredients for metabolism and blood sugar support.
This certification establishes Insumate® as a clinically supported functional ingredient suitable for long-term metabolic health management.
Global expansion: strengthening international presence
According to Fortune Business Insights, the global nutraceuticals market is expected to grow from USD 458.5 billion in 2024 to USD 986.8 billion by 2032, with a CAGR of 10.18%. The Asia Pacific region is expected to exceed 30% of the global market share by 2026, driven by the growing demand for clinically effective and science-based functional ingredients.
Greenyn has established multiple international collaborations and continues to strengthen its presence in the Asia-Pacific region and global markets.
Insumate® has now expanded to over ten countries, achieving commercial launches and demonstrating strong market acceptance in various regions.
The company will continue to deepen and expand its global partnerships while advancing regulatory pathways in Asia, the US and the EU to support long-term international compliance.
Shifting Taiwan’s biotech industry from manufacturing to innovation
Dr. Hsu highlighted that Greenyn has developed several patented ingredients, including Insumate® mcIRBP-19 bitter melon peptide, Antromax® Antrodia cinnamomea mycelium and other proprietary innovations. The company holds over 100 international patents, over 30 global invention awards and is HACCP, ISO 22000, FSSC 22000 and Halal certified. Greenyn provides end-to-end services from raw material development to formulation design and complete ODM/OEM manufacturing.
Greenyn aims to accelerate global collaborations and become the leading provider of scientifically validated functional ingredients in the Asia Pacific region and beyond.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/greenyn-biotechnology-launches-insumate-mcirbp-19-bitter-melon-peptide-targeting-the-billion-dollar-health-supplement-market-302635939.html
SOURCE Greenyn Biotechnology Co., Ltd.
